Roche Announces $5.7 Billion Hostile Takeover Bid for Illumina | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche announced late on Tuesday night a $5.7 billion hostile takeover bid of Illumina.

Under the terms of its all-cash proposed deal, Roche would acquire all outstanding shares of the San Diego-based next-generation sequencing and microarray firm at $44.50 per share, representing a 64 percent premium over the price of Illumina's stock on Dec. 21, 2011, the day before rumors about Roche's interest in Illumina drove up Illumina's stock price, Roche said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.